Top in ID: Biden’s COVID-19 plan, Pfizer vaccine efficacy in children

Last week, the White House unveiled its new COVID-19 plan, which includes a test-to-treat initiative and efforts to enhance surveillance of wastewater for variants. It was the top story in infectious disease.

Another top story was about new research demonstrating the efficacy of the Pfizer-BioNTech COVID-19 vaccine in children and adolescents.

Read these and more top stories in infectious disease below:

‘We have the tools to protect each other’: White House unveils new COVID-19 plan

On the heels of President Joe Biden’s State of the Union address, his administration announced a new National COVID-19 Preparedness Plan, which includes a test-to-treat initiative. Read more.

Real-world evidence shows Pfizer-BioNTech vaccine effective in kids, adolescents

Real-world evidence published Tuesday in MMWR demonstrated that the Pfizer-BioNTech vaccine has protected children and adolescents against COVID-19, including kids aged 5 to 11 years. Read more.

Routine use of typhoid conjugate vaccine could prevent millions of cases

Routine use of a typhoid conjugate vaccine with a catch-up campaign through age 15 years could prevent approximately 67 million cases and 826,000 deaths caused by typhoid fever over 10 years, according to a study. Read more.

MRSA resistance to TMP-SMX increases

A recent study reported an increase in the percentage of MRSA in the United States that was resistant to trimethoprim-sulfamethoxazole from 2012 through 2017. Read more.

NFL’s test-to-release strategy helped vaccinated players shorten isolation time

The NFL’s COVID-19 test-to-release protocol, implemented in December during the omicron surge, helped NFL players and staff members shorten their isolation time, according to a study published in MMWR. Read more.